title: Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI.
abstract: An attempt was made to compare the usefulness of determining markers carcinoembryonic antigen (CEA) and tumor-associated trypsin inhibitor (TATI) in endometrial cancer patients in whom recurrence or distant metastasis was diagnosed in observation after treatment. The study included 316 patients aged 32-81, average age of 61 years, SD = 8.72, with diagnosed endometrial cancer, treated between 1994 and 1995 at the Oncology Center in Warsaw and then under observation from 4 months to 17 years after completion of treatment. The levels of the markers TATI and CEA were assessed from the first five serum samples taken during postoperative radiotherapy and in the initial period of observation after completed treatment. Receiver operating characteristic (ROC) curves were generated, determining the sensitivity and specificity of both CEA and TATI in patients who experienced treatment failure, i.e., recurrence and distant metastasis. Assessing the sensitivity of the marker CEA, it was found that if in the third sample, i.e., during radiation therapy, the marker level increased by more than 20 % compared with the first sample, then recurrence of cancer occurred during the observation period in 75.9 % of patients and metastatic occurred in 69.7 % of patients. In the evaluation of the marker TATI, it was found that if the level of TATI between the first and the third sample increases by 10.6 % from the initial level, then in 84.4 % (sensitivity) of cases, this means the occurrence of cancer recurrence and in 75.7 % (sensitivity) of cases, the occurrence of metastasis. The specificity of both markers is low and not useful diagnostically.
authors.affiliation: M.Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 15 Wawelska St, 02-034, Warsaw, Poland. wum@wp.eu.|Faculty of Health Sciences in Warsaw, Medical University of Warsaw, Warsaw, Poland. wum@wp.eu.
authors.forename: Barbara
authors.initials: B
authors.lastname: Kozakiewicz
authors.affiliation: Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Chądzyńska
authors.affiliation: Faculty of Health Sciences in Warsaw, Medical University of Warsaw, Warsaw, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Dmoch-Gajzlerska
authors.affiliation: Faculty of Health Sciences in Warsaw, Medical University of Warsaw, Warsaw, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Stefaniak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D026921:Amino Acid Transport Systems, Neutral / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D026921:Amino Acid Transport Systems, Neutral; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C498964:SLC16A10 protein, human
keywords: CEA and TATI in endometrial cancer; ROC curves; Sensitivity and specificity of CEA and TATI